CN105410523A - 一种灵芝提取物饮料 - Google Patents
一种灵芝提取物饮料 Download PDFInfo
- Publication number
- CN105410523A CN105410523A CN201510719199.8A CN201510719199A CN105410523A CN 105410523 A CN105410523 A CN 105410523A CN 201510719199 A CN201510719199 A CN 201510719199A CN 105410523 A CN105410523 A CN 105410523A
- Authority
- CN
- China
- Prior art keywords
- beverage
- ganoderma lucidum
- lucidum extract
- ganodenna lucidum
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013361 beverage Nutrition 0.000 title claims abstract description 31
- 240000008397 Ganoderma lucidum Species 0.000 title abstract 10
- 235000001637 Ganoderma lucidum Nutrition 0.000 title abstract 10
- 229940024606 amino acid Drugs 0.000 claims abstract description 16
- 235000001014 amino acid Nutrition 0.000 claims abstract description 16
- -1 compound amino acids Chemical class 0.000 claims abstract description 9
- 150000001413 amino acids Chemical class 0.000 claims abstract description 7
- 235000003599 food sweetener Nutrition 0.000 claims abstract description 7
- 239000003765 sweetening agent Substances 0.000 claims abstract description 7
- 206010019233 Headaches Diseases 0.000 claims abstract description 6
- 231100000869 headache Toxicity 0.000 claims abstract description 6
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims abstract description 6
- 208000024891 symptom Diseases 0.000 claims abstract description 6
- 239000004475 Arginine Substances 0.000 claims abstract description 5
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims abstract description 5
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims abstract description 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 5
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims abstract description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000012141 concentrate Substances 0.000 claims abstract description 5
- 206010022437 insomnia Diseases 0.000 claims abstract description 5
- 229930182817 methionine Natural products 0.000 claims abstract description 5
- 235000015205 orange juice Nutrition 0.000 claims abstract description 5
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims abstract description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims abstract description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000004472 Lysine Substances 0.000 claims abstract description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims abstract description 4
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims abstract description 4
- 239000004299 sodium benzoate Substances 0.000 claims abstract description 4
- 235000010234 sodium benzoate Nutrition 0.000 claims abstract description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims abstract description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims abstract description 3
- 108010011485 Aspartame Proteins 0.000 claims abstract description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims abstract description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims abstract description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims abstract description 3
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims abstract description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229960001230 asparagine Drugs 0.000 claims abstract description 3
- 235000009582 asparagine Nutrition 0.000 claims abstract description 3
- 239000000605 aspartame Substances 0.000 claims abstract description 3
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims abstract description 3
- 235000010357 aspartame Nutrition 0.000 claims abstract description 3
- 229960003438 aspartame Drugs 0.000 claims abstract description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229940013618 stevioside Drugs 0.000 claims abstract description 3
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims abstract description 3
- 235000019202 steviosides Nutrition 0.000 claims abstract description 3
- 239000000811 xylitol Substances 0.000 claims abstract description 3
- 235000010447 xylitol Nutrition 0.000 claims abstract description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 3
- 229960002675 xylitol Drugs 0.000 claims abstract description 3
- 230000000694 effects Effects 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- CEYULKASIQJZGP-UHFFFAOYSA-L disodium;2-(carboxymethyl)-2-hydroxybutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O CEYULKASIQJZGP-UHFFFAOYSA-L 0.000 claims description 3
- 235000000346 sugar Nutrition 0.000 claims description 3
- 208000000059 Dyspnea Diseases 0.000 claims description 2
- 206010013975 Dyspnoeas Diseases 0.000 claims description 2
- 208000008445 altitude sickness Diseases 0.000 abstract description 7
- 238000002474 experimental method Methods 0.000 abstract description 3
- 206010021143 Hypoxia Diseases 0.000 abstract description 2
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 abstract description 2
- 239000003755 preservative agent Substances 0.000 abstract 2
- 230000007954 hypoxia Effects 0.000 abstract 1
- 239000001509 sodium citrate Substances 0.000 abstract 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 abstract 1
- 235000019640 taste Nutrition 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 238000003304 gavage Methods 0.000 description 9
- 239000013641 positive control Substances 0.000 description 6
- 241000700159 Rattus Species 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 241000222336 Ganoderma Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241001165494 Rhodiola Species 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000002567 autonomic effect Effects 0.000 description 2
- 210000004246 corpus luteum Anatomy 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 210000005075 mammary gland Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000008925 spontaneous activity Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010061192 Haemorrhagic fever Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000019926 Keshan disease Diseases 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000001819 pancreatic juice Anatomy 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 210000004560 pineal gland Anatomy 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- HUAUNKAZQWMVFY-UHFFFAOYSA-M sodium;oxocalcium;hydroxide Chemical compound [OH-].[Na+].[Ca]=O HUAUNKAZQWMVFY-UHFFFAOYSA-M 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Non-Alcoholic Beverages (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明公开一种灵芝提取物饮料，涉及饮料领域。本发明由灵芝提取物5-10%、复合氨基酸1-2%、橙汁浓缩液10-20%和适量甜味剂、防腐剂组成的饮料。所述的灵芝提取物为水溶性灵芝提取物，含量为20-30%；所述的复合氨基酸为组氨酸、精氨酸、酪氨酸、天冬酰胺、谷氨酰胺、赖氨酸、色氨酸、蛋氨酸中任一或多个氨基酸的组合；防腐剂为苯甲酸钠，柠檬酸钠；甜味剂为食糖、阿斯巴甜、甜菊甙、木糖醇。本发明用于预防高山反应。所述的高山反应的症状为头痛、失眠、呼吸困难等。本发明有益效果在于既能抗高原反应、口感又好。试验结果显示，本发明可以预防失眠、头痛、缺氧等高反应症状。
Description
技术领域
本发明涉及饮料领域，具体涉及功能饮料领域。
技术背景
灵芝药用在我国已有2000多年的历史，被历代医药家视为滋补强壮、扶正固本的神奇珍品。具有补气安神、止咳平喘的功效，用于眩晕不眠、心悸气短、虚劳咳喘的作用。经过大量临床研究，灵芝对神经衰弱、高脂血症、冠心病心绞痛、心律失常、克山病、高原不适症、肝炎、出血热、消化不良、气管炎等各有不同程度的疗效。但是，需要注意的是，仅仅通过用灵芝食疗这种方法并不能起到明显的防治效果。
氨基酸是人体生命运动中所必须的基本物质。复合氨基酸的用途广泛，人体用可增强人体免疫功能，加强营养吸收等；缓解脑力工作者的脑疲劳睡眠不足引起的各种不良症状；对肝功能、肾功能、肠胃功能均有很好的改善；促进儿童智力开发，增强记忆力。尤其是必需氨基酸,如赖氨酸能促进大脑发育，是肝及胆的组成成分，能促进脂肪代谢，调节松果腺、乳腺、黄体及卵巢，防止细胞退化；色氨酸促进胃液及胰液的产生；苯丙氨酸参与消除肾及膀胱功能的损耗；蛋氨酸(甲硫氨酸)参与组成血红蛋白、组织与血清，有促进脾脏、胰脏及淋巴的功能；苏氨酸有转变某些氨基酸达到平衡的功能；异亮氨酸参与胸腺、脾脏及脑下腺的调节以及代谢；脑下腺属总司令部作用于甲状腺、性腺；亮氨酸：作用平衡异亮氨酸；缬氨酸作用于黄体、乳腺及卵巢。半必需氨基酸和条件必需氨基酸有精氨酸和组氨酸，主治梅毒、病毒性黄疸等病。组氨酸：可作为生化试剂和药剂，还可用于治疗心脏病，贫血，风湿性关节炎等的药物。
如果将复合氨基酸和灵芝提取物合用，可以提高人体的免疫，具有抗高原反应症状的作用。
然而，灵芝提取物味苦；而且，纯的复合氨基酸也有苦味，直接制成咀嚼片，口感不佳
发明内容
发明目的
本发明提供一种灵芝提取物饮料，既能抗高原反应、口感又好。
技术方案
本发明的技术方案为一种灵芝提取物饮料，由灵芝提取物5-10％、复合氨基酸1-2％、橙汁浓缩液10-20％和适量甜味剂、防腐剂制成的饮料。所述的灵芝提取物为水溶性灵芝提取物，含量为20-30％；所述的复合氨基酸为组氨酸、精氨酸、酪氨酸、天冬酰胺、谷氨酰胺、赖氨酸、色氨酸、蛋氨酸中任一或多个氨基酸的组合；防腐剂为苯甲酸钠，柠檬酸钠；甜味剂为食糖、阿斯巴甜、甜菊甙、木糖醇。本发明用于预防高山反应。所述的高山反应的症状为头痛、失眠、呼吸困难等。
有益效果
本发明既能抗高原反应、口感又好。试验结果显示，本发明可以预防失眠、头痛、缺氧等高原反应症状。
具体实施方式
灵芝提取物购自上海康舟真菌多糖有限公司，其含量为20-30％(重量百分比)。实施例1
按重量百分比计，将灵芝提取物10％、组氨酸和精氨酸组成的复方氨基酸1％、橙汁浓缩液20％和适量食糖、苯甲酸钠，加入水中，混匀，即得。
实施例2
按重量百分比计，将灵芝提取物5％、酪氨酸1％、橙汁浓缩液20％和适量甜味剂、柠檬酸钠，加入水中，混匀，即得。
实施例3：
实施例1饮料对常压耐缺氧性能的影响：取50只小鼠随机分为5组：高剂量组、中剂量组、低剂量组，阳性对照组，正常组，每组l0只。正常组按照0.5ml/10g的剂量灌胃生理盐水；阳性对照组灌胃2.0ml红景天口服液；高中低剂量组分别给予实施例1饮料0.5，1.0，2ml灌胃，连续给药7天。末次灌胃给药后1h，将小鼠逐个放入装有10g钠石灰的250mL广口瓶中，瓶盖周围涂抹凡士林密封，使之不漏气，加盖后立即计时；以呼吸停止为标准，起止时间为指标，记录小鼠因缺氧而死亡的时间进行测试。标准缺氧耐受时间计算：T＝(T1-T0)/(V0-W0/0.94)×100(式中：T1为小鼠死亡时间；T0为密闭开始的时间；V0为有效瓶容积；W0为小鼠体重；0.94为排水法测定的小鼠密度)。
表1实施例1饮料对常压耐缺氧性能的影响(means±s)
*p<0.05，**p<0.01与正常组相比
结果：如表1。与正常组小鼠相比，实施例1饮料低、中、高剂量能显著性延长小鼠存活时间(P<0.05)。
实施例4
实施例1饮料的镇静作用：采用自发活动实验，以小鼠作为受试动物，取50只小鼠，雌雄各半，体重为18-22g，随机分为5组：高剂量组、中剂量组、低剂量组，阳性对照组，正常组，每组l0只。正常组按照0.2ml/10g的剂量灌胃生理盐水；阳性对照组灌胃40mg/kg红景天口服液；高中低剂量组分别给予本发明制剂220，110，55mg/kg灌胃，连续给药4天。末次给药50min后，将小鼠依次放入SD-5G型药理生理实验多用仪中，适应环境后，记录5min内小鼠的自主活动次数。
结果：见表2。实施例1饮料高中低剂量能显著性减少小鼠的自主活动次数，与正常组比较有显著性差异(P<0.05)。
表2实施例1饮料对小鼠自发活动次数的影响(means±s)
*p<0.05，**p<0.01与正常组相比
实施例5：
实施例1饮料对头痛的作用：采用大鼠偏头痛模型试验。取50只大鼠随机分为5组：高剂量组、中剂量组、低剂量组，阳性对照组，模型组，每组l0只。模型组按照3.0ml/100g的剂量灌胃生理盐水；阳性对照组灌胃5.0ml红景天口服液；高中低剂量组分别给予实施例1饮料2.0，4.0，6.0ml灌胃，连续给药7天，第4天给药后，除空白组外腹腔注射硝酸甘油，造偏头痛模型，剂量10mg/kg。连续3天，在末次造模后4小时内观察行为学指标：大鼠挠头或甩头次数及出现和消除的时间。
表3实施例1饮料对偏头痛的影响(means±s)
*p<0.05，**p<0.01与模型组相比
结果：如表3。动物造模后30min左右，均出现双耳发红、前肢频繁搔头,爬笼次数增多,烦躁不安现象。治疗组动物在给药后，上述现象逐渐消失,趋于正常。模型组动物上述现象持续约3小时，继而出现蜷卧，活动减少状态。与模型组小鼠相比，实施例1饮料低、中、高剂量能显著性减少大鼠挠头和甩头的次数(P<0.05)。
Claims (6)
1.一种灵芝提取物饮料，其特征在于：按重量百分比计，由灵芝提取物5-10%、复合氨基酸1-2%、橙汁浓缩液10-20%和适量甜味剂、防腐剂组成的饮料。
2.根据权利要求书1所述的灵芝提取物饮料，其特征在于：所述的复合氨基酸为组氨酸、精氨酸、酪氨酸、天冬酰胺、谷氨酰胺、赖氨酸、色氨酸、蛋氨酸中任一或多个氨基酸的组合。
3.根据权利要求书1所述的灵芝提取物饮料，其特征在于：所述的防腐剂为苯甲酸钠，柠檬酸钠。
4.根据权利要求书1所述的灵芝提取物饮料，其特征在于：所述的甜味剂为食糖、阿斯巴甜、甜菊甙、木糖醇。
5.根据权利要求书1-4任一所述的灵芝提取物饮料的应用，其特征在于：用于预防高山反应。
6.根据权利要求书5所述的灵芝提取物饮料的应用，其特征在于：所述的高山反应的症状为头痛、失眠、呼吸困难等。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510719199.8A CN105410523A (zh) | 2015-10-29 | 2015-10-29 | 一种灵芝提取物饮料 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510719199.8A CN105410523A (zh) | 2015-10-29 | 2015-10-29 | 一种灵芝提取物饮料 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105410523A true CN105410523A (zh) | 2016-03-23 |
Family
ID=55489444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510719199.8A Pending CN105410523A (zh) | 2015-10-29 | 2015-10-29 | 一种灵芝提取物饮料 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105410523A (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20030097173A (ko) * | 2002-06-19 | 2003-12-31 | (주) 다정 | 홍삼 음료 |
| CN103054855A (zh) * | 2012-12-25 | 2013-04-24 | 常州亚当生物技术有限公司 | 一种组合物及其制备方法、应用 |
| CN104256816A (zh) * | 2014-09-16 | 2015-01-07 | 广东东阳光药业有限公司 | 一种食用菌氨基酸饮料及其制备方法 |
-
2015
- 2015-10-29 CN CN201510719199.8A patent/CN105410523A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20030097173A (ko) * | 2002-06-19 | 2003-12-31 | (주) 다정 | 홍삼 음료 |
| CN103054855A (zh) * | 2012-12-25 | 2013-04-24 | 常州亚当生物技术有限公司 | 一种组合物及其制备方法、应用 |
| CN104256816A (zh) * | 2014-09-16 | 2015-01-07 | 广东东阳光药业有限公司 | 一种食用菌氨基酸饮料及其制备方法 |
Non-Patent Citations (1)
| Title |
|---|
| 李韶华: "灵芝饮料的制法", 《企业技术开发》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111035649B (zh) | 一种nmn+glp复配营养补充剂及其制备方法和应用 | |
| CN104083352A (zh) | 对于肺部病症的治疗 | |
| CN106806853A (zh) | 一种缓解体力疲劳和/或提高缺氧耐受力的中药组合物、其制备方法和应用 | |
| CN107320674B (zh) | 一种改善认知、延缓痴呆病情进展的中药组合物及其应用 | |
| Welgama et al. | Varicella-zoster virus infection in the infectious diseases hospital, Sri Lanka | |
| CN105193839A (zh) | 一种抗高原反应制剂及其应用 | |
| CN101991548A (zh) | 还原型谷胱甘肽冻干粉针剂及其制备方法 | |
| CN107518121A (zh) | 一种缓解体力疲劳的天然组合物及其制备方法 | |
| CN105288416A (zh) | 一种治疗儿童多动症的中药 | |
| CN105410523A (zh) | 一种灵芝提取物饮料 | |
| CN104000181A (zh) | 一种用于缓解体力疲劳的组合物及其制备方法 | |
| CN102240341B (zh) | 一种平喘滴丸的制备方法 | |
| CN101450048B (zh) | 替普瑞酮的一种抗急性低氧损伤用途 | |
| CN105192810A (zh) | 一种复合氨基酸饮料及其制备方法、应用 | |
| CN105249104A (zh) | 一种冬虫夏草菌丝体饮料及其应用 | |
| CN102357115A (zh) | 无糖型复方扶芳藤合剂及其生产方法 | |
| CN108030074B (zh) | 提高高原耐低氧适应能力的复合营养制剂及其制备方法 | |
| Wang et al. | Prospects of molecular hydrogen in perioperative neuroprotection from basic research to clinical application | |
| CN104225201A (zh) | 一种治疗咳嗽的药物组合物 | |
| CN102406722A (zh) | 一种抗缺氧药物组合物及制备方法及用途 | |
| CN103585570A (zh) | 一种解酒醒神的中药组合物 | |
| CN108126008A (zh) | 迷迭香虫草丸 | |
| CN103013801B (zh) | 一种增强免疫力、抗疲劳的保健酒 | |
| CN103798755A (zh) | 一种用于抗疲劳的胶囊 | |
| CN102813210B (zh) | 一种保健食品 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160323 |
|
| WD01 | Invention patent application deemed withdrawn after publication |